The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has maintained its leadership through its sustainability strategy which is fully embedded in the company’s business and culture. “We are proud of being recognised once again for our sustainability efforts,” says Roche CEO Severin Schwan. “At Roche, we know that the…
Read More »
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations…
You might be interested in
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…
The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies…
The FINANCIAL — Bayer announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and the…

The FINANCIAL — Roche today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning…
You might be interested in
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index…
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…
The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies…

The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment to be…
You might be interested in
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index…
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…
The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies…

The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma…
You might be interested in
In 2017, Ninja Theory, advised by Cambridge academic Professor Paul Fletcher, took the gaming world by storm with Hellblade, which…
The FINANCIAL — It is often believed that a close relationship between owners and their dogs can bring many mental health…
The FINANCIAL — Blood pressure should be measured in both arms and the higher reading should be adopted to improve hypertension…
Discovery sets the stage for development of new therapies to treat vitelliform macular dystrophy. Using a new imaging technique, researchers…
The FINANCIAL — Roche and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in…
You might be interested in
Older people are likely to be vaccinated regardless of party affiliation. New research from the University of Georgia suggests age and…
SARS-CoV-2 infection can trigger the production of immune molecules that damage cells lining blood vessels in the brain, causing platelets…
The FINANCIAL — COVID-19 was the third leading cause of death in the United States between March 2020 and October…
In the UK, there were 346 deaths involving COVID-19 registered in the week ending 24 June 2022, an increase from…
The FINANCIAL — Roche today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive…
You might be interested in
The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index…
The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm…
The FINANCIAL — Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a…
The FINANCIAL — On the occasion of the World Health Assembly, the world’s research-based and generic & biosimilar pharmaceutical industry bodies…

The FINANCIAL — Commenting on the Group’s sales in the first nine months, Roche CEO Severin Schwan said: “Roche is at the forefront of the fight against COVID-19 with a growing portfolio of diagnostics solutions, the development of new medicines and a number of partnerships across the industry. With the recent launch of the rapid…
You might be interested in
The FINANCIAL — Globally-significant events have driven recent financial market volatility and contributed to the emergence of a risk-off environment, according…
Commodity and risk currencies rallied overnight on reports the US may soon rollback tariffs on Chinese consumer goods. Asian stock…
The FINANCIAL — Even with the tremendous volatility in the sector, there are many more traditional hedge funds investing in…
Are you considering the amount of earnings and savings in relation to the future? Do you already own a savings account…

THe FINANCIAL — Roche announced that it intends to launch a high-volume SARS-CoV-2 Antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The test is planned to be made available at the end of 2020 for markets accepting the CE Mark. Roche also intends to file for…
You might be interested in
Older people are likely to be vaccinated regardless of party affiliation. New research from the University of Georgia suggests age and…
SARS-CoV-2 infection can trigger the production of immune molecules that damage cells lining blood vessels in the brain, causing platelets…
The FINANCIAL — COVID-19 was the third leading cause of death in the United States between March 2020 and October…
In the UK, there were 346 deaths involving COVID-19 registered in the week ending 24 June 2022, an increase from…